09:57 AM EST - Aptose Biosciences Inc. : Today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose’s Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine. Aptose Biosciences Inc.
shares T.APTO are trading up $0.07 at $0.32.
